From Department of Cardiology, Boston Children's Hospital, MA (S.D.d.F., M.M.M.); Institute for Clinical Research and Health Policy Studies (A.M.R., L.K.L., R.C.S.) and Division of Clinical Decision Making (J.B.W.), Tufts Medical Center, Boston, MA; and Boston University School of Medicine, MA (M.M.M.).
Circulation. 2016 Mar 15;133(11):1067-72. doi: 10.1161/CIRCULATIONAHA.115.018791.
The prevalence of familial hypercholesterolemia (FH) is commonly reported as 1 in 500. European reports suggest a higher prevalence; the US FH prevalence is unknown.
The 1999 to 2012 National Health and Nutrition Examination Survey (NHANES) participants ≥20 years of age (n=36 949) were analyzed to estimate the prevalence of FH with available Dutch Lipid Clinic criteria, including low-density lipoprotein cholesterol and personal and family history of premature atherosclerotic cardiovascular disease. Prevalence and confidence intervals of probable/definite FH were calculated for the overall population and by age, sex, obesity status (body mass index ≥30 kg/m(2)), and race/ethnicity. Results were extrapolated to the 210 million US adults ≥20 years of age. The estimated overall US prevalence of probable/definite FH was 0.40% (95% confidence interval, 0.32-0.48) or 1 in 250 (95% confidence interval, 1 in 311 to 209), suggesting that 834 500 US adults have FH. Prevalence varied by age, being least common in 20 to 29 year olds (0.06%, 1 in 1557) and most common in 60 to 69 year olds (0.85%, 1 in 118). FH prevalence was similar in men and women (0.40%, 1 in 250) but varied by race/ethnicity (whites: 0.40%, 1 in 249; blacks: 0.47%, 1 in 211; Mexican Americans: 0.24%, 1 in 414; other races: 0.29%, 1 in 343). More obese participants qualified as probable/definite FH (0.58%, 1 in 172) than nonobese (0.31%, 1 in 325).
FH, defined with Dutch Lipid Clinic criteria available in NHANES, affects 1 in 250 US adults. Variations in prevalence by age and obesity status suggest that clinical criteria may not be sufficient to estimate FH prevalence.
家族性高胆固醇血症(FH)的患病率通常报道为每 500 人中 1 人。欧洲的报告表明患病率更高;而美国 FH 的患病率尚不清楚。
分析了 1999 年至 2012 年国家健康和营养检查调查(NHANES)中≥20 岁的参与者(n=36949),以根据荷兰血脂诊所标准估计 FH 的患病率,包括低密度脂蛋白胆固醇以及个人和家族史中有早发性动脉粥样硬化性心血管疾病。计算了总体人群以及按年龄、性别、肥胖状况(体重指数≥30kg/m²)和种族/族裔分类的可能/确定 FH 的患病率和置信区间。将结果外推至 2.1 亿≥20 岁的美国成年人。估计美国总体可能/确定 FH 的患病率为 0.40%(95%置信区间,0.32-0.48)或 1 比 250(95%置信区间,1 比 311 至 209),提示美国有 834500 名成年人患有 FH。患病率随年龄而变化,在 20 至 29 岁人群中最为常见(0.06%,1 比 1557),在 60 至 69 岁人群中最为常见(0.85%,1 比 118)。男性和女性的 FH 患病率相似(0.40%,1 比 250),但因种族/族裔而异(白人:0.40%,1 比 249;黑人:0.47%,1 比 211;墨西哥裔美国人:0.24%,1 比 414;其他种族:0.29%,1 比 343)。更多肥胖参与者符合可能/确定 FH 的标准(0.58%,1 比 172),而非肥胖参与者(0.31%,1 比 325)。
根据 NHANES 中可用的荷兰血脂诊所标准定义,FH 影响每 250 名美国成年人中的 1 人。患病率随年龄和肥胖状况的变化表明,临床标准可能不足以估计 FH 的患病率。